All Stories

  1. Major vault protein (MVP) suppresses aging- and estrogen deficiency-related bone loss through Fas-mediated apoptosis in osteoclasts

    Article • Cell Death and Disease, September 2023, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  2. Macrophage MVP regulates fracture repair by promoting M2 polarization via JAK2-STAT6 pathway

    Article • International Immunopharmacology, July 2023, Elsevier

    Dr Erik A.C. Wiemer

  3. In desmoid-type fibromatosis cells sorafenib induces ferroptosis and apoptosis, which are enhanced by autophagy inhibition

    Article • European Journal of Surgical Oncology, July 2022, Elsevier

    Dr Erik A.C. Wiemer

  4. Major Vault Protein Prevents Atherosclerotic Plaque Destabilization by Suppressing Macrophage ASK1-JNK Signaling

    Article • Arteriosclerosis Thrombosis and Vascular Biology, May 2022, Wolters Kluwer Health

    Dr Erik A.C. Wiemer

  5. miR-196b-5p and miR-107 Expression Differentiates Ocular Sebaceous Carcinoma from Squamous Cell Carcinoma of the Conjunctiva

    Article • International Journal of Molecular Sciences, April 2022, MDPI AG

    Dr Erik A.C. Wiemer

  6. Role of Lipid Rafts in Pathogen-Host Interaction - A Mini Review

    Article • Frontiers in Immunology, January 2022, Frontiers

    Dr Wen Chang, Dr Erik A.C. Wiemer

  7. Connecting the mammalian immune system with bacterial chemical signaling

    Article • Proceedings of the National Academy of Sciences, March 2021, Proceedings of the National Academy of Sciences

    Michael Meijler, Dr Erik A.C. Wiemer

  8. Major vault protein (MVP) negatively regulates osteoclastogenesis via calcineurin-NFATc1 pathway inhibition

    Article • Theranostics, January 2021, Ivyspring International Publisher

    Dr Erik A.C. Wiemer

  9. Differentially Methylated Regions in Desmoid-Type Fibromatosis: A Comparison Between CTNNB1 S45F and T41A Tumors

    Article • Frontiers in Oncology, October 2020, Frontiers

    Dr Erik A.C. Wiemer, Dr ir Wilfred van IJcken

  10. Non-Coding RNAs, a Novel Paradigm for the Management of Gastrointestinal Stromal Tumors

    Article • International Journal of Molecular Sciences, September 2020, MDPI AG

    Dr Erik A.C. Wiemer

  11. Major Vault Protein Promotes Hepatocellular Carcinoma Through Targeting Interferon Regulatory Factor 2 and Decreasing p53 Activity

    Article • Hepatology, March 2020, Wiley

    Dr Erik A.C. Wiemer

  12. Cell-type-specific role of CHK2 in mediating DNA damage-induced G2 cell cycle arrest

    Article • Oncogenesis, March 2020, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  13. Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors

    Article • Scientific Reports, February 2020, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  14. A new carboxamide probe as On-Off fluorescent and colorimetric sensor for Fe3+ and application in detecting intracellular Fe3+ ion in living cells

    Article • Journal of Photochemistry and Photobiology A Chemistry, February 2020, Elsevier

    Dr Erik A.C. Wiemer

  15. MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma

    Article • PLoS ONE, January 2020, PLOS

    Dr Erik A.C. Wiemer, Dr ir Wilfred van IJcken

  16. The Prognostic Role of β-Catenin Mutations in Desmoid-type Fibromatosis Undergoing Resection Only

    Article • Annals of Surgery, December 2019, Wolters Kluwer Health

    Dr Erik A.C. Wiemer

  17. Inhibition of activin-like kinase 4/5 attenuates cancer cachexia associated muscle wasting

    Article • Scientific Reports, July 2019, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  18. Uncovering the signaling landscape controlling breast cancer cell migration identifies novel metastasis driver genes

    Article • Nature Communications, July 2019, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  19. Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs

    Article • Cancers, June 2019, MDPI AG

    Dr Erik A.C. Wiemer

  20. Aberrant MicroRNA Expression and Its Implications for Uveal Melanoma Metastasis

    Article • Cancers, June 2019, MDPI AG

    Dr Erik A.C. Wiemer

  21. Activated Signaling Pathways and Targeted Therapies in Desmoid-Type Fibromatosis: A Literature Review

    Article • Frontiers in Oncology, May 2019, Frontiers

    Dr Erik A.C. Wiemer

  22. MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines

    Article • PLoS ONE, May 2019, PLOS

    Dr Erik A.C. Wiemer

  23. Major vault protein suppresses obesity and atherosclerosis through inhibiting IKK–NF-κB signaling mediated inflammation

    Article • Nature Communications, April 2019, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  24. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations

    Article • European Journal of Surgical Oncology, April 2019, Elsevier

    Dr Erik A.C. Wiemer

  25. Tissue-Specific Chk1 Activation Determines Apoptosis by Regulating the Balance of p53 and p21

    Article • iScience, February 2019, Elsevier

    Dr Erik A.C. Wiemer

  26. The versatile nature of miR-9/9* in human cance

    Article • Oncotarget, March 2018, Impact Journals, LLC

    Dr Erik A.C. Wiemer

  27. Major Vault Protein, a Candidate Gene in 16p11.2 Microdeletion Syndrome, Is Required for the Homeostatic Regulation of Visual Cortical Plasticity

    Article • Journal of Neuroscience, March 2018, Society for Neuroscience

    Dr Erik A.C. Wiemer

  28. Prognostic Circulating MicroRNA Biomarkers in Early-Stage Non-Small Cell Lung Cancer: A Role for miR-150

    Article • Clinical Pharmacology & Therapeutics, December 2017, Wiley

    Dr Erik A.C. Wiemer

  29. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors

    Article • PLoS ONE, August 2017, PLOS

    Dr Erik A.C. Wiemer

  30. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial

    Article • European Journal of Cancer, April 2017, Elsevier

    Dr Erik A.C. Wiemer

  31. Loss of SLCO1B3 drives taxane resistance in prostate cancer

    Article • British Journal of Cancer, August 2016, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  32. Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation

    Article • The Prostate, March 2016, Wiley

    Dr Erik A.C. Wiemer

  33. Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment

    Article • European Journal of Cancer, March 2016, Elsevier

    Dr Erik A.C. Wiemer

  34. Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Caba...

    Article • European Urology, March 2016, Elsevier

    Dr Erik A.C. Wiemer

  35. MiR-193b promotes autophagy and non-apoptotic cell death in oesophageal cancer cells

    Article • BMC Cancer, February 2016, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  36. Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice

    Article • British Journal of Pharmacology, February 2016, Wiley

    Dr Erik A.C. Wiemer

  37. Inducible Major Vault Protein Plays a Pivotal Role in Double-Stranded RNA– or Virus-Induced Proinflammatory Response

    Article • The Journal of Immunology, February 2016, The American Association of Immunologists

    Dr Erik A.C. Wiemer

  38. miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway

    Article • Molecular Cancer, November 2015, Springer Science + Business Media

    Dr Erik A.C. Wiemer, Dr ir Wilfred van IJcken

  39. 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes

    Article • British Journal of Clinical Pharmacology, August 2015, Wiley

    Dr Erik A.C. Wiemer

  40. Lysosomal Sequestration Determines Intracellular Imatinib Levels

    Article • Molecular Pharmacology, June 2015, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Erik A.C. Wiemer

  41. Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients

    Article • Breast Cancer Research and Treatment, June 2015, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  42. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer

    Article • European Urology, June 2015, Elsevier

    Dr Erik A.C. Wiemer

  43. MicroRNA regulation of RAD51 in serous ovarian cancer modulates chemotherapy response

    Article • JNCI Journal of the National Cancer Institute, May 2015, Oxford University Press (OUP)

    Dr Erik A.C. Wiemer

  44. Phase I Study of Cisplatin, Hyperthermia, and Lapatinib in Patients With Recurrent Carcinoma of the Uterine Cervix in a Previously Irradiated Area

    Article • The Oncologist, February 2015, Alphamed Press

    Dr Erik A.C. Wiemer

  45. Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence

    Article • Clinical Pharmacokinetics, February 2015, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  46. Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors

    Article • Clinical Cancer Research, July 2014, American Association for Cancer Research (AACR)

    Dr Erik A.C. Wiemer

  47. MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3α

    Article • BMC Cancer, June 2014, Springer Science + Business Media

    Dr Erik A.C. Wiemer, Dr ir Wilfred van IJcken

  48. MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors

    Article • International Journal of Cancer, January 2014, Wiley

    Dr Erik A.C. Wiemer, Dr ir Wilfred van IJcken

  49. DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity

    Article • Molecular Oncology, December 2013, Wiley

    Dr Erik A.C. Wiemer, Dr ir Wilfred van IJcken

  50. Incident cancer risk after the start of aspirin use: Results from a Dutch population-based cohort study of low dose aspirin users

    Article • International Journal of Cancer, December 2013, Wiley

    Dr Erik A.C. Wiemer

  51. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer

    Article • European Journal of Cancer, December 2013, Elsevier

    Dr Erik A.C. Wiemer

  52. Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors

    Article • Clinical Cancer Research, August 2013, American Association for Cancer Research (AACR)

    Dr Erik A.C. Wiemer

  53. MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours

    Article • British Journal of Cancer, August 2013, Springer Science + Business Media

    Dr Erik A.C. Wiemer, Dr ir Wilfred van IJcken

  54. A Pharmacogenetic Predictive Model for Paclitaxel Clearance Based on the DMET Platform

    Article • Clinical Cancer Research, August 2013, American Association for Cancer Research (AACR)

    Dr Erik A.C. Wiemer

  55. Gene Expression Profiling of Histiocytic Sarcomas in a Canine Model: The Predisposed Flatcoated Retriever Dog

    Article • PLoS ONE, August 2013, PLOS

    Dr Erik A.C. Wiemer

  56. The issue of non-specific binding of cabazitaxel

    Article • Journal of Chromatography B, August 2013, Elsevier

    Dr Erik A.C. Wiemer

  57. Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?

    Article • Blood, June 2013, American Society of Hematology

    Dr Erik A.C. Wiemer

  58. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen

    Article • Breast Cancer Research and Treatment, June 2013, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  59. CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity

    Article • Clinical Cancer Research, May 2013, American Association for Cancer Research (AACR)

    Dr Erik A.C. Wiemer

  60. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs

    Article • April 2013, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  61. Evaluation of Patient Enrollment in Oncology Phase I Clinical Trials

    Article • The Oncologist, February 2013, Alphamed Press

    Dr Erik A.C. Wiemer

  62. Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer

    Article • Breast Cancer Research and Treatment, January 2013, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  63. The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin

    Article • European Journal of Cancer, January 2013, Elsevier

    Dr Erik A.C. Wiemer

  64. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells

    Article • Oncogene, October 2012, Springer Science + Business Media

    Dr Erik A.C. Wiemer, Dr ir Wilfred van IJcken

  65. A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients

    Article • Clinical Cancer Research, July 2012, American Association for Cancer Research (AACR)

    Dr Erik A.C. Wiemer

  66. Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy

    Article • Clinical Cancer Research, May 2012, American Association for Cancer Research (AACR)

    Dr Erik A.C. Wiemer

  67. Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: A practical solution for non-specific binding

    Article • Journal of Pharmaceutical and Biomedical Analysis, February 2012, Elsevier

    Dr Erik A.C. Wiemer

  68. Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry

    Article • Journal of Pharmaceutical and Biomedical Analysis, December 2011, Elsevier

    Dr Erik A.C. Wiemer

  69. Stressed tumor cell, chemosensitized cancer

    Article • Nature Reports Stem Cells, December 2011, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  70. Recruitment of the Major Vault Protein by InlK: A Listeria monocytogenes Strategy to Avoid Autophagy

    Article • PLoS Pathogens, August 2011, PLOS

    Dr Erik A.C. Wiemer

  71. Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: A prospective cross-over drug–drug interaction study

    Article • European Journal of Cancer, April 2011, Elsevier

    Dr Erik A.C. Wiemer

  72. microRNAs in stage I epithelial ovarian cancer

    Article • The Lancet Oncology, March 2011, Elsevier

    Dr Erik A.C. Wiemer

  73. Drug transporters of platinum-based anticancer agents and their clinical significance

    Article • Drug Resistance Updates, February 2011, Elsevier

    Dr Erik A.C. Wiemer

  74. Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry

    Article • Journal of Pharmaceutical and Biomedical Analysis, January 2011, Elsevier

    Dr Erik A.C. Wiemer

  75. Drug Transporters and Imatinib Treatment: Implications for Clinical Practice

    Article • Clinical Cancer Research, December 2010, American Association for Cancer Research (AACR)

    Dr Erik A.C. Wiemer

  76. Role of MicroRNAs in Anti-cancer Drug Resistance

    Article • December 2010, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  77. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation

    Article • European Journal of Cancer, November 2010, Elsevier

    Dr Erik A.C. Wiemer

  78. Effects of methimazole on the elimination of irinotecan

    Article • Cancer Chemotherapy and Pharmacology, August 2010, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  79. MicroRNAs in ovarian cancer biology and therapy resistance

    Article • The International Journal of Biochemistry & Cell Biology, August 2010, Elsevier

    Dr Erik A.C. Wiemer

  80. Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study

    Article • Cancer Chemotherapy and Pharmacology, July 2010, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  81. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry

    Article • Journal of Pharmaceutical and Biomedical Analysis, March 2010, Elsevier

    Dr Erik A.C. Wiemer

  82. MicroRNA markers for forensic body fluid identification obtained from microarray screening and quantitative RT-PCR confirmation

    Article • International Journal of Legal Medicine, February 2010, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  83. A CYP3A4 Phenotype-Based Dosing Algorithm for Individualized Treatment of Irinotecan

    Article • Clinical Cancer Research, January 2010, American Association for Cancer Research (AACR)

    Dr Erik A.C. Wiemer

  84. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)

    Article • British Journal of Pharmacology, January 2010, Wiley

    Dr Erik A.C. Wiemer

  85. Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry

    Article • Journal of Pharmaceutical and Biomedical Analysis, December 2009, Elsevier

    Dr Erik A.C. Wiemer

  86. MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response

    Article • The EMBO Journal, June 2009, Wiley

    Dr Erik A.C. Wiemer, Dr ir Wilfred van IJcken

  87. The Applicability of mTOR Inhibition in Solid Tumors

    Article • Current Cancer Drug Targets, May 2009, Bentham Science Publishers

    Dr Erik A.C. Wiemer

  88. Abrogation of DNA vector-based RNAi during apoptosis in mammalian cells due to caspase-mediated cleavage and inactivation of Dicer-1

    Article • Cell Death and Differentiation, February 2009, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  89. Application of prolonged microdialysis sampling in carboplatin-treated cancer patients

    Article • Cancer Chemotherapy and Pharmacology, December 2008, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  90. The spliceosome as target for anticancer treatment

    Article • British Journal of Cancer, November 2008, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  91. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer

    Article • Proceedings of the National Academy of Sciences, September 2008, Proceedings of the National Academy of Sciences

    Dr Erik A.C. Wiemer

  92. In Reply

    Article • Journal of Clinical Oncology, July 2008, American Society of Clinical Oncology (ASCO)

    Dr Erik A.C. Wiemer

  93. Editorial: The Long and Winding Road to Better Cancer Cell-Specific Therapies

    Article • The Oncologist, May 2008, Alphamed Press

    Dr Erik A.C. Wiemer

  94. A small mammal model of tumour implantation, dissemination and growth factor expression after partial hepatectomy

    Article • European Journal of Surgical Oncology, April 2008, Elsevier

    Dr Erik A.C. Wiemer

  95. Dose Selection in Phase I Studies: Why We Should Always Go for the Top

    Article • Journal of Clinical Oncology, April 2008, American Society of Clinical Oncology (ASCO)

    Dr Erik A.C. Wiemer

  96. W1985 MicroRNA Expression Profiling of Colorectal Cancer and Its Precancerous Lesions Using Lna™ Oligonucleotide Arrays

    Article • Gastroenterology, April 2008, Elsevier

    Dr Erik A.C. Wiemer

  97. Renal Function as a Predictor of Irinotecan-induced Neutropenia

    Article • Clinical Pharmacology & Therapeutics, February 2008, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  98. Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment

    Article • Nature Clinical Practice Oncology, February 2008, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  99. Pitfalls of the application of microdialysis in clinical oncology: Controversial findings with docetaxel

    Article • Journal of Pharmaceutical and Biomedical Analysis, October 2007, Elsevier

    Dr Erik A.C. Wiemer

  100. Host Resistance to Lung Infection Mediated by Major Vault Protein in Epithelial Cells

    Article • Science, July 2007, American Association for the Advancement of Science

    Dr Erik A.C. Wiemer

  101. The role of microRNAs in cancer: No small matter

    Article • European Journal of Cancer, July 2007, Elsevier

    Dr Erik A.C. Wiemer

  102. Improved Insight into Resistance Mechanisms to Imatinib in Gastrointestinal Stromal Tumors: A Basis for Novel Approaches and Individualization of Treatment

    Article • The Oncologist, June 2007, Alphamed Press

    Dr Erik A.C. Wiemer

  103. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients

    Article • Clinical Pharmacology & Therapeutics, November 2006, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  104. Practical Aspects of Managing Gastrointestinal Stromal Tumors

    Article • Clinical Colorectal Cancer, November 2006, Elsevier

    Dr Erik A.C. Wiemer

  105. The Relevance of Microdialysis for Clinical Oncology

    Article • Current Clinical Pharmacology, September 2006, Bentham Science Publishers

    Dr Erik A.C. Wiemer

  106. Vault mobility depends in part on microtubules and vaults can be recruited to the nuclear envelope

    Article • Experimental Cell Research, November 2005, Elsevier

    Dr Erik A.C. Wiemer

  107. Major Vault Protein, in Concert with Constitutively Photomorphogenic 1, Negatively Regulates c-Jun–Mediated Activator Protein 1 Transcription in Mammalian Cells

    Article • Cancer Research, July 2005, American Association for Cancer Research (AACR)

    Dr Erik A.C. Wiemer

  108. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

    Article • Blood, November 2004, American Society of Hematology

    Dr Erik A.C. Wiemer

  109. Efflux Kinetics and Intracellular Distribution of Daunorubicin Are Not Affected by Major Vault Protein/Lung Resistance-Related Protein (Vault) Expression

    Article • Cancer Research, July 2004, American Association for Cancer Research (AACR)

    Dr Erik A.C. Wiemer

  110. Resistance to Platinum-Containing Chemotherapy in Testicular Germ Cell Tumors Is Associated with Downregulation of the Protein Kinase SRPK1

    Article • Neoplasia, July 2004, Elsevier

    Dr Erik A.C. Wiemer

  111. Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine

    Article • BJU International, June 2004, Wiley

    Dr Erik A.C. Wiemer

  112. The Major Vault Protein Is a Novel Substrate for the Tyrosine Phosphatase SHP-2 and Scaffold Protein in Epidermal Growth Factor Signaling

    Article • Journal of Biological Chemistry, May 2004, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Erik A.C. Wiemer, Professor Anton M Bennett

  113. The formation of vault-tubes: a dynamic interaction between vaults and vault PARP

    Article • Journal of Cell Science, November 2003, The Company of Biologists

    Dr Erik A.C. Wiemer

  114. Vaults: a ribonucleoprotein particle involved in drug resistance?

    Article • Oncogene, October 2003, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  115. The vault complex

    Article • Cellular and Molecular Life Sciences, September 2003, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  116. Unimpaired dendritic cell functions in MVP/LRP knockout mice

    Article • Immunology, September 2003, Wiley

    Dr Erik A.C. Wiemer

  117. The genomic sequence of the murine major vault protein and its promoter

    Article • Gene, July 2002, Elsevier

    Dr Erik A.C. Wiemer

  118. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)

    Article • Leukemia, May 2002, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  119. Selection and characterisation of a phage-displayed human antibody (Fab) reactive to the lung resistance-related major vault protein

    Article • British Journal of Cancer, March 2002, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  120. Structural Domains of Vault Proteins: A Role for the Coiled Coil Domain in Vault Assembly

    Article • Biochemical and Biophysical Research Communications, March 2002, Elsevier

    Dr Erik A.C. Wiemer

  121. Up-Regulation of Drug Resistance-Related Vaults During Dendritic Cell Development

    Article • The Journal of Immunology, February 2002, The American Association of Immunologists

    Dr Erik A.C. Wiemer

  122. Multiple Human Vault RNAs

    Article • Journal of Biological Chemistry, July 2001, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Erik A.C. Wiemer

  123. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia

    Article • Blood, June 2001, American Society of Hematology

    Dr Erik A.C. Wiemer

  124. Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML)

    Article • Leukemia, May 2001, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  125. MDR1 expression in poor-risk acute myeloid leukemia with partial or complete monosomy 7

    Article • Leukemia, March 2001, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  126. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer

    Article • Current Opinion in Oncology, November 2000, Wolters Kluwer Health

    Dr Erik A.C. Wiemer

  127. Inhibitors of multidrug resistance

    Article • Current Opinion in Oncology, November 1997, Wolters Kluwer Health

    Dr Erik A.C. Wiemer

  128. Visualization of the Peroxisomal Compartment in Living Mammalian Cells: Dynamic Behavior and Association with Microtubules

    Article • The Journal of Cell Biology, January 1997, Rockefeller University Press

    Dr Erik A.C. Wiemer

  129. Signals, Receptors, and Cytosolic Factors Involved in Peroxisomal Protein Import

    Article • Annals of the New York Academy of Sciences, December 1996, Wiley

    Dr Erik A.C. Wiemer

  130. Identification of 2-enoyl coenzyme A hydratase and NADP+-dependent 3-hydroxyacyl-CoA dehydrogenase activity in glycosomes of procyclic Trypanosoma brucei

    Article • Molecular and Biochemical Parasitology, November 1996, Elsevier

    Professor Fred R. Opperdoes, Dr Erik A.C. Wiemer

  131. Isolation and Characterization of Pas2p, a Peroxisomal Membrane Protein Essential for Peroxisome Biogenesis in the Methylotrophic YeastPichia pastoris

    Article • Journal of Biological Chemistry, August 1996, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Erik A.C. Wiemer

  132. Human peroxisomal targeting signal-1 receptor restores peroxisomal protein import in cells from patients with fatal peroxisomal disorders

    Article • The Journal of Cell Biology, July 1995, Rockefeller University Press

    Dr Erik A.C. Wiemer

  133. Molecular analysis of glyceraldehyde-3-phosphate dehydrogenase in Trypanoplasma borelli: An evolutionary scenario of subcellular compartmentation in Kinetoplastida

    Article • Journal of Molecular Evolution, April 1995, Springer Science + Business Media

    Professor Fred R. Opperdoes, Dr Erik A.C. Wiemer

  134. Protein Import Deficiencies in Human Peroxisomal Disorders

    Article • January 1994, Elsevier

    Dr Erik A.C. Wiemer

  135. Topology of catalase assembly in human skin fibroblasts

    Article • Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, December 1993, Elsevier

    Dr Erik A.C. Wiemer

  136. The electrochemical proton gradient in the bloodstream form of Trypanosoma brucei is dependent on the temperature

    Article • Molecular and Biochemical Parasitology, October 1992, Elsevier

    Professor Fred R. Opperdoes, Dr Erik A.C. Wiemer

  137. Production and characterisation of monoclonal antibodies against native and disassembled human catalase

    Article • Journal of Immunological Methods, July 1992, Elsevier

    Dr Erik A.C. Wiemer

  138. Pyruvate transport across the plasma membrane of the bloodstream form of Trypanosoma brucei is mediated by a facilitated diffusion carrier

    Article • Biochemical and Biophysical Research Communications, April 1992, Elsevier

    Professor Fred R. Opperdoes, Dr Erik A.C. Wiemer

  139. Phenotypic heterogeneity in cultured skin fibroblasts from patients with disorders of peroxisome biogenesis belonging to the same complementation group

    Article • Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, October 1991, Elsevier

    Dr Erik A.C. Wiemer

  140. Prenatal Diagnosis of Zellweger Syndrome by Direct Visualization of Peroxisomes in Chorionic Villus Fibroblasts by Immunofluorescence Microscopy

    Article • Journal of Inherited Metabolic Disease, April 1989, Springer Science + Business Media

    Dr Erik A.C. Wiemer

  141. Kinetics of the assembly of peroxisomes after fusion of complementary cell lines from patients with the cerebro-hepato-renal (Zellweger) syndrome and related disorders

    Article • Biochemical and Biophysical Research Communications, May 1988, Elsevier

    Dr Erik A.C. Wiemer